Abbott (ABT) Tops Q1 EPS by 2c; Boosts FY16 EPS Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
BTIG Believes Abbot (ABT) May be Renegotating Terms of Alere (ALR) Deal; Affirms at 'Buy'
April 20, 2016 2:27 PM EDTBTIG affirms Abbot Labs (NYSE: ABT) at Buy with a price target of $45 and comments on Alere (NYSE: ALR) chatter following commentary from Abbott CEO Miles White earlier.
Analyst Dane Leone said: Comments from CEO Miles... More
